1. Home
  2. Azioni
  3. Stati Uniti
  4. Nasdaq
  5. Incyte Corporation
  6. SocietÓ
    INCY   US45337C1027

INCYTE CORPORATION

(INCY)
  Rapporto
RiassuntoQuotazioniGraficiNotizieRatingCalendarioSocietÓFinanzaConsensusRevisioniDerivati 
AttivitÓ
Logo Incyte Corporation
Incyte Corporation Ŕ specializzata nella ricerca e sviluppo di prodotti terapeutici destinati principalmente al trattamento di tumori e disturbi infiammatori. Le vendite nette sono ripartite per fonte di reddito come segue:
- vendite di prodotti (77,7%);
- royalties (19,1%);
- entrate da accordi di ricerca e cooperazione (3,2%).

Numero di dipendenti : 2 094 persone.
Vendite per attivitÓ
20202021Delta
Proprietary Therapeutics2 068.7477.6%2 322.0177.8% +12.24%
Product Royalty392.9714.7%569.2619.1% +44.86%
Milestone and Contract205.007.7%95.003.2% -53.66%
USD in Milioni
Vendite per regione
20202021Delta
United States1 937.8572.7%2 139.1871.6% +10.39%
Global597.9722.4%669.1722.4% +11.91%
Europe105.003.9%109.403.7% +4.18%
China and Taiwan25.881%68.532.3% +164.76%
USD in Milioni
Dirigenti
Nome Titolo EtÓ Da
HervÚ Hoppenot Chairman, President & Chief Executive Officer 61 2015
Christiana Stamoulis Chief Financial Officer & Executive Vice President 50 2019
Steven Stein Chief Medical Officer & Executive Vice President 54 2016
Dashyant Dhanak Chief Scientific Officer & Executive VP 60 2018
Lauren Ayala Senior Director-Investor Relations - -
Maria Pasquale Secretary, Executive VP & General Counsel 55 -
Robert Newton, Dr. Vice President-Pharmacology - -
Keith Mikkelson, Dr. Executive Director-Business Development - -
Barry Flannelly, Dr. EVP & General Manager-North America 63 2015
Phillip Liu, Dr. Associate Director-Applied Technology - -
Amministratori
Nome Titolo EtÓ Da
HervÚ Hoppenot Chairman, President & Chief Executive Officer 61 2015
Julian Charles Baker Lead Independent Director 54 -
Wendy L. Dixon, Dr. Independent Director 65 2011
Jean-Jacques BienaimÚ Independent Director 67 2015
Paul J. Clancy Independent Director 59 2015
Jacqualyn A. Fouse, Dr. Independent Director 59 2017
Edmund P. Harrigan, Dr. Independent Director 68 2019
Katherine A. High, Dr. Independent Director 69 2020
Otis W. Brawley, Dr. Independent Director 62 2021
Azioni
Voto QuantitÓFlottanteAutocontrolloFlottante totale
Azione A 1 221 505 011 218 057 767 98.4% 0 0.0% 98.4%
Azionisti
NomeAzioni%
Baker Bros. Advisors LP 36 675 682 16,6%
The Vanguard Group, Inc. 20 166 978 9,11%
Dodge & Cox 16 657 586 7,53%
SSgA Funds Management, Inc. 9 347 709 4,22%
Wellington Management Co. LLP 9 008 491 4,07%
T. Rowe Price Associates, Inc. (Investment Management) 7 271 688 3,29%
Columbia Wanger Asset Management LLC 5 295 000 2,39%
Durus Capital Management LLC 4 944 800 2,23%
Renaissance Technologies LLC 4 590 733 2,07%
BlackRock Fund Advisors 4 516 125 2,04%
Partecipazioni
NomeAzioni%Valorizzazione
MERUS N.V. (MRUS) 3 550 000 8,15% 72 420 000 USD
AGENUS INC. (AGEN) 12 070 195 4,69% 22 329 861 USD
Mercati e indici
- Nasdaq Global Select Market
- Nasdaq 100 / S&P 500
Codici di Borsa
- Codice Bloomberg :  
- Codice Reuters :  INCY.O
- Codice Datastream :  
Coordinate societÓ
Incyte Corporation
1801 Augustine Cut-Off
DE 19803 Wilmington, Delaware

Telefono : +1 855 446 2983
Fax :
Internet : https://www.incyte.com
Portafoglio di marchi
In collaborazione conAllbrands.markets
Pi¨ marchi di Incyte Corporation
Settore Prodotti farmaceutici - Altri
Var. 1genCapi. (M$)
INCYTE CORPORATION1.28%16 586
JOHNSON & JOHNSON1.68%465 705
PFIZER, INC.-11.14%294 404
ELI LILLY AND COMPANY8.19%269 013
ABBVIE INC.11.53%266 851
ROCHE HOLDING AG-15.67%266 707
NOVO NORDISK A/S3.58%245 099
MERCK & CO., INC.22.06%236 570
ASTRAZENECA PLC20.93%202 681
NOVARTIS AG8.00%193 025
BRISTOL-MYERS SQUIBB COMPANY22.20%162 213
SANOFI15.49%134 759
AMGEN INC.10.01%132 214
GLAXOSMITHKLINE PLC9.80%111 286
BAYER AG35.62%66 062
DAIICHI SANKYO CO., LTD.13.20%49 636
CHUGAI PHARMACEUTICAL CO., LTD-5.33%45 478
TAKEDA PHARMACEUTICAL COMPANY LIMITED18.87%45 016
JIANGSU HENGRUI MEDICINE CO., LTD.-40.37%28 822
ASTELLAS PHARMA INC.4.92%27 643
ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL., LTD-30.05%27 566